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Abstract
Objective This study aimed to assess the cost impact of
administering erythropoiesis-stimulating agents once every
4 weeks instead of one to three times a week to treat
anaemia in patients undergoing dialysis.
Methods This was a monocentric retrospective study
involving 27 patients who underwent haemodialysis
between 2009 and 2013 in a university hospital in Angers,
France. The study was a cost-minimisation analysis from
the hospital perspective. Only direct medical costs were
considered.
Results This study demonstrated that therapeutic manage-
ment of anaemia with methoxy polyethylene glycol-epo-
etin beta would save medical and nurse time (7 days and
15 days per year, respectively) and reduce costs by €59,960
a year for an active file of 40 patients undergoing
haemodialysis, assuming a 100% occupancy rate in the
above-mentioned hospital.
Conclusion This study indicated that treating anaemia by
administering erythropoiesis-stimulating agents once every
4 weeks instead of one to three times a week in patients
undergoing haemodialysis would be beneficial for the
hospital.
Key Points for Decision Makers
This study aimed to assess the cost impact of
implementing a new therapeutic strategy for treating
anaemia in patients undergoing dialysis.
Treating anaemia with methoxy polyethylene glycol-
epoetin beta in patients undergoing haemodialysis
may reduce costs related to the management of these
patients in a hospital environment.
1 Introduction
The incidence of chronic kidney failure continues to
increase in developed countries. This condition gradually
progresses to end-stage chronic kidney failure, which
requires replacement therapy—extra-renal purification or
kidney transplant. This sustained increase in prevalence
means that chronic kidney failure has become a significant
public health concern in many countries, including France.
According to the French National Authority for Health
(Haute Autorite´ de Sante´ [HAS]) guidance note, Medical
and Economical Assessment of Kidney Failure Manage-
ment Strategies in France (September 2010), the preva-
lence of chronic kidney failure in France is one of the
highest after the USA and Germany. French Renal Epi-
demiology and Information Network data from 31
December 2013 [1] estimated that 76,187 people were
undergoing replacement therapy by dialysis or kidney
transplant (i.e. 1163 people treated per 1 million inhabi-
tants), 44% of whom were living with functional kidney
grafts and 56% of whom were undergoing dialysis.
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One of the consequences of chronic kidney failure is
anaemia caused by insufficient synthesis of erythropoiesis.
It can cause systolic dysfunction and heart failure [2–4],
and treating it in patients with chronic kidney failure
increases the survival rate, reduces morbidity and improves
quality of life.
In June 2013 [5], HAS published best practice guideli-
nes for treating chronic kidney failure-related anaemia in
order to slow the progression of heart complications and
improve patients’ quality of life. According to a recent
HAS report [6], best practice guidelines set a target hae-
moglobin concentration of between 9 and 13 g/dl in
patients undergoing haemodialysis being treated with an
erythropoiesis-stimulating agent (ESA).
In 2007, a new ESA with a long half-life and a dosing
schedule of one injection every 4 weeks reached the mar-
ket. Therefore, an assessment of the cost impact of
implementing a new type of management was justified.
Given the frequencyof thedisease and thecost of purchasing
ESAs, treating anaemia in patients with chronic kidney failure
is a major economic challenge. Evaluating the factors that
define the medical costs related to ESAs can support decision
making in the selection of the most efficient ESA for treating
anaemia in patients with chronic kidney failure.
A literature review [7–9] indicated that administering
methoxy polyethylene glycol (MPG)-epoetin beta once a
month reduced costs and saved time; however, the results
were not unanimous and key criteria were heterogeneous,
making comparison difficult.
The Tempo [10] study assessed the amount of time that
would be saved by switching from several injections a week
(or twice a month) to one monthly injection. The results of
this French study indicated that switching to one monthly
injection would save up to 32.5 days of work per patient and
per year for pharmacists/pharmacy technicians and nurses.
The results of these various works, combined with the
current context of budget cuts and the search for efficiency,
confirm the relevance of our study.
The objective of this study was to demonstrate whether
treating anaemia with MPG-epoetin beta in patients
undergoing dialysis reduced costs related to the manage-
ment of these patients in a hospital environment. If so, this
could translate into cost savings because of the time saved,
mainly for nurses, which could in turn lead to a reorgani-
sation of the haemodialysis service.
2 Methods
2.1 Design of the Study
Several studies [11, 12] have demonstrated that the effi-
ciency and tolerance of MPG-epoetin beta is equal to that
of erythropoietins. Furthermore, on 19 December 2007, the
French Transparency Committee [13] concluded that
‘‘MPG-epoetin beta has been as efficient as the other ery-
thropoiesis-stimulating agents and has a similar tolerance
profile,’’ confirming these results. Therefore, we chose to
evaluate this new type of management using a cost-min-
imisation analysis.
A cost-utility analysis may have been possible. How-
ever, our study compared two therapeutic strategies (ad-
ministration three times a week vs. once every 4 weeks)
that have no direct impact on patients’ quality of life.
Indeed, patients are unaware of ESA administration
because it occurs directly at the dialysis generator; neither
the number of dialyses nor the general care of the patient
changes. However, the literature review [2–5] did show
that treating anaemia slows the progression of heart com-
plications and reduces morbidity, thereby improving
patient quality of life. Furthermore, the retrospective nature
of our study meant we could not ask patients to complete a
quality-of-life questionnaire, particularly as some of the
patients had died.
This is a retrospective monocentric comparative ‘before/
after’ study in which patients acted as their own control.
We calculated only direct medical costs as defined in the
traditional terminology of economic evaluation described
in the French College of Health Economists methodologi-
cal guide for the economic assessment of health strategies
[14]. The study was conducted from the hospital’s per-
spective and compared two methods of managing anaemia:
administration of ESA one to three times a week (ery-
thropoietin alpha or beta) versus every 4 weeks (MPG-
epoetin beta).
Our hypothesis was that the implementation of a new
administration method for treating anaemia in patients
undergoing dialysis could reduce management costs in a
French hospital environment.
2.2 Study Population
The population included patients aged [18 years under-
going haemodialysis who had anaemia that had been
treated with an ESA one to three times a week over a
6-month period and a pegylated ESA once every 4 weeks
over a subsequent 6-month period. This study enabled the
comparison of two populations of patients (Fig. 1). Con-
version from erythropoietin alpha or beta to MPG-epoetin
Fig. 1 Schema of the two periods of study
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beta complied with the summary of product characteristics
recommendations: The initial dose of MPG-epoetin beta
was calculated based on the weekly dose of erythropoietin
alpha or beta previously administered at the time of the
substitution, and the first injection began on the date
planned in the previous administration schedule for the
erythropoietin alpha or beta.
Each patient acted as their own control. There were two
types of measured parameters: fixed variables, measured
once when the patient entered the study, and time-related
variables, measured every month during the study. Data
collection was retrospective over the period between 2009
and 2013.
2.3 Cost-Minimisation Analysis
The cost-minimisation analysis was carried out from the
hospital perspective. Data were collected via follow-up of the
cohort of patients undergoinghaemodialysiswhowere treated
with an ESA or a pegylated ESA between 2009 and 2013. The
year of valuation corresponded to the year of ESA adminis-
tration (2009–2013). Costs were calculated from negotiated
real prices adjusted year to year. Unit cost values are detailed
in Table 1. The evaluation was conducted over a 12-month
period and assessed the direct medical costs (Table 2) related
to resources that were likely to vary between the two thera-
peutic strategies over the time horizon. The costs were esti-
mated according to a sophisticated approach to the real costs
(micro-costing) and are expressed in €.
The average medical time per prescription of ESA
represents the exclusive time for prescription with regard to
the results of the biological balance sheet and was obtained
from real-world timing. The physician was the same person
(a single physician) in both before and after groups.
We conducted a univariate deterministic sensitivity
analysis (tornado diagram) using three relevant variables:
– time for ESA prescription per practitioner,
– time for ESA administration per nurse,
– cost of acquiring ESA.
Medical time includes the time from receiving the bio-
logical results and entering the data into the system until
the prescription of ESAs. Nursing care time includes the
time spent administering the ESAs, including removing the
ESA from the refrigerator, disinfecting the injection area,
preliminary control of the ESA according to the patient and
the prescription (verifying concordance between patient
identity and the dose prescribed for this patient before
administering the ESA), administering the ESA (injection)
and logging the administration (electronic traceability).
3 Results
3.1 Statistical Analysis of the Population
A total of 27 patients who underwent haemodialysis
between 2009 and 2013 were eligible for this study
(Fig. 2); 62% were men, and the average age was
70.3 ± 11.5 years. Diabetes (37.9%) and hypertension
(58.6%) were the main cardiovascular risk factors. All
patients were monitored in the haemodialysis service. The
average ratio spKt/V (used to measure haemodialysis
adequacy) was 1.6 ± 0.3.
Table 1 Description of the unit
cost values
Variable Unit cost values (€)
Average hourly pay for hospital physician: 2010 42
Hourly pay for nurse: 2010 25
ESAs one to three times per week (varies according to year) 0.0035–0.0074 per IU
ESAs every 4 weeks (varies according to year) 1.4294–1.6234 per lg
Iron (varies according to year) 6.1260–13.2526 per vial
ESA erythropoiesis-stimulating agent
Table 2 Description of the direct medical costs and method of their calculation
Cost description Method of calculating the costs
Medical time for the prescription of ESAs Average medical time per ESA prescription 9 number of prescriptions
Nursing care time for the administration of ESAs Average nursing care time per ESA administration 9 number of administrations
Acquiring ESAs Price, including all taxes, per unit 9 number of units administered
Acquiring injectable iron Price, including all taxes, per unit 9 number of units administered
Administering ESAs (technical medical procedures) Number of procedures for ESA administration 9 two AMI
Administering injectable iron (technical medical procedures) Number of procedures for injectable iron administration 9 2 AMI
AMI Acte Me´dico Infirmier (nursing procedure), ESA erythropoiesis-stimulating agent
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No patients were naı¨ve to ESAs. All patients had been
treated with erythropoietin alpha or beta for at least
6 months then with MPG-epoetin beta for at least
6 months. The average administered dose of erythropoietin
alpha or beta was 7389 IU per week or 29,556 IU per
month. The average administered dose of MPG-epoetin
beta was 148 lg per month (range 33–381).
The average blood haemoglobin level was 11.2 ± 1.1 g/
dl in the ‘before’ population and 11.0 ± 1.2 g/dl in the
‘after’ population. Moreover, the haemoglobin level for
96% of patients matched the target of 9–13 g/dl recom-
mended by the HAS, both in those following the 6-month
treatment with erythropoietin alpha or beta and in those
following the 6-month treatment with MPG-epoetin beta.
Only one patient in the ‘before’ population did not reach
(8.9 g/dl) the haemoglobin target recommended by HAS.
This did not influence the cost-minimisation analysis of
this group or the robustness of the cost-minimisation
analysis in this study.
Iron supplementation was performed according to good
practice and adjusted to maintain adequate iron status
(ferritin[ 100 ng/ml and transferrin saturation
[TSAT][ 20%). The percentage of patients receiving
supplementary iron at baseline was similar in each treat-
ment group: MPG-epoetin beta 96% and erythropoietin
alpha or beta 96%.
In total, 16 patients experienced one serious side effect
and were hospitalised at least once in the course of the
study. The most frequently observed serious side effects
were influenza-like illness (five patients), deep vein
thrombosis (two patients) and thrombosis at the fistula (two
patients). Other less frequently observed serious side
effects included sepsis, pulmonary oedema, respiratory
distress, delirium and poorly controlled hypertension.
3.2 Results of the Cost-Minimisation Analysis
3.2.1 Cost Measurement
We considered only the direct medical costs related to the
implementation of the two therapeutic strategies, which
included all costs for hospital care (Table 3).
The cost-minimisation analysis showed that treating
anaemia with MPG-epoetin beta in patients undergoing
haemodialysis saved €40,464 per year (€133,166 vs.
92,702; Wilcoxon p = 0.031), corresponding to €1499 per
patient per year. This represents savings of €59,960 per
year for an active file of 40 patients (assuming a 100%
occupancy rate).
A univariate deterministic sensitivity analysis (tornado
diagram; Figs. 3, 4) carried out on three relevant variables
(Table 4) confirmed these results were robust.
Fig. 2 Cohort of eligible
patients
Table 3 Direct medical costs
according to the type of anaemia
treatment






Medical time for ESA prescription 33.9 h 17.4 h
Cost of medical time for ESA prescription €1424 €731
Nursing care time for ESA administration 39.4 h 5.5 h
Nursing care for ESA administration €984 €138
Acquiring ESAs €44,528 €38,058
ESA administration (AMI) €13,054 €1134
Acquiring injectable iron €4401 €3978
Injectable iron administration (AMI) €2192 €2312
Total €66,583 €46,351
AMI Acte Me´dico Infirmier (nursing procedure), ESA erythropoiesis-stimulating agent, MPG methoxy
polyethylene glycol
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These sensitivity analyses showed that the cost of
acquiring ESAs had the greatest impact on the overall cost.
This is particularly pronounced in the ‘before’ population.
The results showed that treating anaemia with MPG-epo-
etin beta saved 49% of practitioner time over 1 year, rep-
resenting 33 h per year or 1.2 h per patient per year. It also
saved 7 days of medical time per year for an active file of
40 patients per year. The results showed that treating
anaemia with MPG-epoetin beta saved 87% of nurse time
over 1 year, representing 68 h per year or 2.5 h per patient
per year. It saved 15 days of nursing care time per year for
an active file of 40 patients per year.
The results of this study therefore confirm the hypothesis
that treating anaemia with MPG-epoetin beta in patients
undergoing haemodialysis may reduce the costs related to
the management of these patients in a hospital environment.
4 Discussion
This study demonstrated that administering ESAs once
every 4 weeks instead of one to three times a week saved
7 days of medical time and 15 days of nursing care time
per year.
This result confirms those of Schmid [9] and the Tempo
[10] study. Schmid [9] showed that changing the treatment
of anaemia to MPG-epoetin beta could save a significant
amount of nursing care time, but the majority of included
studies were retrospective.
This result also confirms those of a recent prospective
study [15] that found MPG-epoetin beta to be more cost
effective than erythropoietin beta (incremental cost-effec-
tiveness ratio continuous erythropoietin receptor activator
vs. epoetin beta at -$US6457.5, year 2013 values), making
it the dominant treatment for the management of anaemia
in patients receiving chronic haemodialysis.
Another recent cost-utility analysis [16] suggested that
managing anaemia with MPG-epoetin beta compared with
epoetin beta in patients receiving dialysis may result in better
outcomes with higher overall costs, but there were limitations.
It is important to mention that patients receiving dialysis
have a higher risk of mortality due to cardiac complica-
tions. Indeed, anaemia increases the work output of the
heart by favouring left ventricular hypertrophy and
remodelling the big arteries. Therefore, administration of
erythropoietin would limit cardiac complications. Further-
more, erythropoietin, a hormone with antioxidant and anti-
apoptosis effects, has a protective effect against ischemia
Fig. 3 Graphical representation
of the univariate sensitivity
analysis (tornado diagram) on
the ‘before’ population
Fig. 4 Graphical representation
of the univariate sensitivity
analysis (tornado diagram) on
the ‘after’ population
Table 4 Average value (€) and
confidence interval of the
variables used for the sensitivity
study
Variables Average value (95% confidence interval)
‘Before’ population ‘After’ population
Cost in time for ESA prescription per practitioner 1424 (567–2268) 731 (340–1134)
Cost in time for ESA administration per nurse 984 (777–1727) 138 (75–225)
Cost of acquiring ESA 44,528 (33,604–70,087) 38,058 (34,970–39,342)
ESA erythropoiesis-stimulating agent
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reperfusion. This hormone also controls angiogenesis and
increases endothelial cells in the process of tissue repair.
However, erythropoietin can also cause high blood pres-
sure. Thus, it is important that haemoglobin concentration
is stable around its target value. This indicates ESAs with a
long half-life [4] are of clinical interest.
Treating anaemia with long half-life ESAs requires
fewer administrations, which in turn appears to limit the
risk of mortality by reducing variations in haemoglobin
levels. Indeed, variations in haemoglobin concentrations
appear to increase the risk of mortality, likely because of
the repeated episodes of tissue ischemia that negatively
affect organs such as the heart.
The amount of time saved (15 days per year for an
active file of 40 patients per year) would allow nurses to
allocate time to improving the quality of their work, in turn
enhancing the quality and overall safety of care.
The change in management strategies also showed cost
benefits: treating anaemia with MPG-epoetin beta in
patients undergoing haemodialysis would save €59,960 per
year for the 40 patients currently undergoing haemodialysis
in this hospital.
These results confirm some results in the literature.
Ranchon et al. [7] showed that direct medical costs, par-
ticularly the costs of purchasing ESAs, account for the
largest portion of direct medical costs. Our sensitivity
analyses also showed that the cost of acquiring ESAs had
the greatest impact on overall costs.
In our study, the administered dose of MPG-epoetin beta
varied between 33 and 381 lg per month, with an average
administered dose of 148 lg per month. Our results
showed that changing anaemia treatment to MPG-epoetin
beta reduced treatment costs.
This study has limitations. We examined direct medical
costs but not side effects associated with ESA treatment.
Furthermore, the small size of our sample means these
results only show a trend, and it would be interesting to
undertake another study in several centres to increase the
cohort size. This would strengthen the observations sug-
gested by this pilot study. It would also be interesting to
include side effects associated with anaemia treatment and
data on patient survival and quality of life.
In conclusion, treating anaemia with MPG-epoetin beta
in patients undergoing haemodialysis may reduce costs
related to the management of these patients in a hospital
environment.
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